The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
News|Podcasts|August 4, 2023
What to Know About the Approval of Lecanemab-irmb
Nikhil Palekar discusses the FDA approval of lecanemab-irmb (Leqembi, Eisai) and what this means for those who have Alzheimer Disease.
Advertisement
In an interview with Pharmacy Times, Nikhil Palekar, MD, director of the Stony Brook Center of Excellence for Alzheimer Disease, director of the Stony Brook Division for Geriatric Psychiatry, and director of the Stony Brook Alzheimer Disease clinical trials program, discussed the FDA approval of lecanemab-irmb (Leqembi, Eisai) and what this means for those who have Alzheimer Disease.
Although the treatment is not a cure and cannot reverse early Alzheimer disease, Palekar said it could give patients crucial more time to join other clinical trials investigating potential treatments.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Advertisement
Advertisement